Arecor to present at Oppenheimer conference
Arecor Therapeutics plc announced it will present its lead program, AT278, an ultra-concentrated, ultra-rapid acting insulin, at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026. The company will also attend the Advanced Technologies & Treatments for Diabetes (ATTD) conference from March 11-14, 2026. These presentations and attendance highlight Arecor's focus on developing improved therapeutics for diabetes and cardiometabolic diseases, particularly its AT278 formulation designed to reduce patient burden and enhance automated insulin delivery systems.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 9 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be presenting at the Oppenheimer 36th Annual Healthcare MedTech and Services Conference on 16 March. The Arecor team will also be attending the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 11-14 March. Full details for both events are below:
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 16-19 March 2026, online
Sarah Howell will be presenting on Arecor's lead programme AT278, the only ultra-concentrated, ultra-rapid acting insulin, designed to lower patient burden and improve outcomes for people with diabetes in combination with Automated Insulin Delivery (AID) Systems, at the Oppenheimer conference on March 16, 2026 at 9.20am EDT. Click here to register to watch the presentation. The presentation will also be made available on Arecor's website here after the event. David Ellam, CFO, will also be attending.
Advanced Technologies & Treatments for Diabetes (ATTD) - 11-14 March 2026, Barcelona
Sarah Howell (CEO), Jan Jezek (CSO) and David Gerring (CDO) will also be attending ATTD 2026. The conference brings clinicians, diabetes care providers, researchers, industry, investors, reimbursement authorities, and regulators together in order to collaborate to drive rapid progress in diabetes care.
For attendees at either conference interested in meeting the Arecor team, please email BD@arecor.com.
About AT278
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.